Is Certara, Inc. (CERT) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 27.2% / 30% | 16.8% / 30% | 10.3% / 30% | 1.51% / 5% | ✓ HALAL |
| DJIM | 27.2% / 33% | 16.8% / 33% | 10.3% / 33% | 1.51% / 5% | ✓ HALAL |
| MSCI | 19.7% / 33% | 12.2% / 33% | 7.5% / 33% | 1.51% / 5% | ✓ HALAL |
| S&P | 27.2% / 33% | 16.8% / 33% | 10.3% / 33% | 1.51% / 5% | ✓ HALAL |
| FTSE | 19.7% / 33% | 12.2% / 33% | 7.5% / 50% | 1.51% / 5% | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 61.5% | |
| Operating Margin | 2.1% | |
| Net Margin | -0.4% | |
| Return on Equity (ROE) | -0.1% | |
| Return on Assets (ROA) | 0.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $96M |
| Free Cash Flow | $70M |
| Total Debt | $306M |
| Debt-to-Equity | 29.0 |
| Current Ratio | 2.1 |
| Total Assets | $1.6B |
Price & Trading
| Last Close | $6.14 |
| 50-Day MA | $7.41 |
| 200-Day MA | $9.78 |
| Avg Volume | 2.9M |
| Beta | 1.6 |
|
52-Week Range
$5.71
| |
About Certara, Inc. (CERT)
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.
Purification Calculator
As a halal stock with 1.51% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Certara, Inc. (CERT) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Certara, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Certara, Inc.'s debt ratio?
Certara, Inc.'s debt ratio is 27.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 19.7%.
Does Certara, Inc. require dividend purification?
Yes, Certara, Inc. has an impermissible income ratio of 1.51%, which means 1.51% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are Certara, Inc.'s key financial metrics?
Certara, Inc. has a market capitalization of $916M, and revenue of $419M. The company maintains a gross margin of 61.5% and a net margin of -0.4%. Return on equity stands at -0.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.